In this 48-year-old patient, for whom neurosurgery was not feasible due to the macroadenoma's extension, treatment with pasireotide LAR successfully improved prolactin, GH and normalised IGF-1 levels, while tumour size remained stable. Here, GH1 is linked to neoplasm.